W. Longo

Publications70
h-index20
Citations1,706
Highly Influential Citations48
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Robins
  • 230 Publications, 6,270 Citations
  • B. Kahl
  • 462 Publications, 12,754 Citations
  • R. Storb
  • 1,383 Publications, 83,629 Citations
  • O. Hermine
  • 1,116 Publications, 33,592 Citations
  • Publications
  • Influence
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow…
We report the results of a phase III open-label, randomized, multicenter trial comparing tacrolimus/methotrexate to cyclosporine/methotrexate for graft-versus-host disease (GVHD) prophylaxis after… Expand
  • 478
  • 17
Intussusception of the appendix: comprehensive review of the literature.
BACKGROUND Intussusception of the appendix is a rare disease that constitutes a diagnostic challenge to the surgeon. The literature on this condition is limited to case reports. The demographics,… Expand
  • 68
  • 8
Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
PURPOSE To evaluate the biologic interactions and toxicities of carboplatin combined with 41.8 degrees C whole-body hyperthermia (WBH) for 60 minutes in a phase I clinical trial. PATIENTS AND… Expand
  • 30
  • 3
Anastomotic disruption after large bowel resection.
Anastomotic disruption is a feared and serious complication of colon surgery. Decades of research have identified factors favoring successful healing of anastomoses as well as risk factors for… Expand
  • 49
  • 3
Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemia
The augmented Berlin–Frankfurt–Münster (aBFM) regimen has demonstrated improved outcomes in children with acute lymphomblastic leukemia (ALL), but efficacy in adults is unknown. In this retrospective… Expand
  • 34
  • 3
  • PDF
Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
Bevacizumab is the fi rst vascular endothelial growth factor-targeted agent shown to increase survival in patients receiving first- and second-line intravenous 5-FU-based chemotherapy for the… Expand
  • 35
  • 2
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial…
Allogeneic (allo) hematopoietic cell transplantation (HCT) can induce long-term remissions in chemosensitive relapsed follicular lymphoma (FL). The Blood and Marrow Transplant Clinical Trials Network… Expand
  • 26
  • 2
Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose…
PurposeRetreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced… Expand
  • 23
  • 2
  • PDF
Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
2510Background: Anti-CD19 CAR-T cell therapy is a breakthrough treatment (tx) for patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Despite impressive outcomes, non-r...
  • 18
  • 2
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
BACKGROUND There is no standard first line treatment for mantle cell lymphoma. PATIENTS AND METHODS This was a multicenter phase II pilot study of rituximab and modified hyper-fractionated… Expand
  • 101
  • 1